Peptide Profile
Chonluten
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Dose Range
5-10mg
Frequency
Once daily
Route
Sublingual (enteric-coated capsules)
Cycle Length
12+ weeks
Onset
Gradual (3-4 weeks)
Evidence
Limited
Compound Profile
Scientific & Efficacy Data
C11H17N3O8
Molecular Formula
319.27 g/mol
Molecular Weight
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
Half-Life
Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
Bioavailability
75007-24-8
CAS #
194641
PubChem ID ↗
Developed By · 1990s-2000s (developed as part of Khavinson's systematic organ-specific peptide bioregulator research program)
Thorne Research / BioResource International
Thorne Research Inc.
Primary Benefits
Amino Acid Sequence
DGEA-GFOGER-GPQGIAG-GSKGPDDosing
How much
do I take?
Starting Dose
1-2 capsules (5 mg each) sublingually once daily
Begin with the conservative oral protocol using enteric-coated capsules. Take on an empty stomach 15-30 minutes before meals for optimal absorption. The EDG tripeptide is designed for oral bioavailability through peptide transporters. Effects are gradual — bronchopulmonary gene expression changes build over the treatment course. Monitor respiratory function and note any changes in breathing comfort.
Standard Dose
5-10 mg subcutaneously or 2 capsules orally once daily
Standard Khavinson bioregulator protocol for bronchopulmonary support. Administer once daily for 10-20 consecutive days. Repeat courses every 3-6 months for sustained respiratory benefits. Can be combined with Vladonix for comprehensive immune-respiratory support or Epithalon for systemic geroprotection. The epigenetic changes initiated during treatment persist beyond the active course.
Advanced Dose
10 mg subcutaneously once daily
Extended protocol for significant respiratory compromise or advanced geroprotective programs. Used in clinical studies as part of comprehensive multi-peptide bioregulator therapy for elderly patients. Often combined with Vladonix (thymic), Epithalon (pineal), Vilon (immune), and Cerluten (brain) for whole-body bioregulation. Repeat courses every 3-6 months. Medical supervision recommended.
Timing
Best time to take
Take Chonluten at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Chonluten can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Chonluten should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
- ×Pregnancy and breastfeeding — insufficient reproductive safety data
- ×Active pulmonary infections requiring immediate medical treatment
- ×Severe immunosuppression without medical supervision — immunomodulatory effects may be unpredictable
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Chonluten use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Chonluten in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Chonluten is administered Sublingual (enteric-coated capsules)—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your Chonluten formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Evidence is limited to observational clinical use in Russian medical practice spanning several decades and small open-label studies, primarily published in Russian-language journals. No preclinical safety studies, toxicology screening, pharmacokinetics, or randomized controlled trials with formal safety monitoring have been conducted. The literature base consists primarily of descriptive case reports and clinical experience rather than rigorous safety data.
Common Side Effects
Experienced by some users
Injection site reaction
Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. Standard for injectable peptide bioregulators.
Management: Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Mild fatigue
Slight fatigue during initial days as bronchopulmonary immune function recalibrates and respiratory gene expression programs activate.
Management: Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Transient respiratory changes
Mild increase in mucus production or slight changes in respiratory secretions as bronchial epithelial normalization occurs.
Management: Generally benign — indicates active epithelial remodeling. Stay hydrated. Should stabilize within several days.
Mild headache
Transient headache during the first few days of treatment, potentially related to immune activation and cytokine level adjustment.
Management: Ensure adequate hydration. Standard analgesics if needed. Usually self-limiting.
Less Common
- •Flu-like symptoms
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Chonluten
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Chonluten should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Immunosuppressive medications (cyclosporine, tacrolimus) — Chonluten's immunomodulatory effects may counteract immunosuppression - Use with caution—discuss with your healthcare provider.
- !High-dose systemic corticosteroids — may interfere with Chonluten's bronchial epithelial differentiation mechanisms - Use with caution—discuss with your healthcare provider.
- !Other potent immunostimulants at high doses without medical supervision — risk of immune overactivation in pulmonary tissue - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Chonluten. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Limited human trials
What to Expect
Days 1-10 (during treatment course)
What you might notice
- •Minimal noticeable changes initially — epigenetic mechanisms targeting bronchopulmonary genes are building
- •Possible mild injection site reactions or respiratory changes as epithelial remodeling begins
- •Mild fatigue as pulmonary immune function adjusts
- •DNA minor groove binding at ATTTC sequences is activating respiratory gene transcription
What's normal
- •Effects are subtle at first — Chonluten works at the gene expression level through DNA promoter binding
- •Ki-67 and p53 normalization in bronchial epithelium is beginning but cellular turnover takes days to weeks
- •TNF tolerance induction in alveolar macrophages is starting to reduce inflammatory signaling
What's next
- →Continue daily administration for the full course duration (10-20 days)
- →Respiratory improvements will continue building as epithelial differentiation progresses
- →The most significant cellular changes occur during and shortly after the treatment course
Week 2-6 (during and after treatment)
What you might notice
- •Improved respiratory comfort and breathing capacity
- •Enhanced mucociliary clearance and reduced respiratory congestion
- •Better resilience against respiratory infections and environmental irritants
- •Improved energy levels as pulmonary gas exchange normalizes
What's normal
- •Bronchial epithelial differentiation is significantly improved with normalized cell turnover
- •Alveolar macrophage inflammation is substantially reduced through TNF tolerance
- •Pro-inflammatory cytokine levels (IL-1β, IL-6, TNF-α) are markedly decreased
- •These molecular changes translate into functional respiratory improvements over weeks
What's next
- →Benefits continue developing for weeks after the treatment course ends
- →Epigenetic modifications to bronchopulmonary gene expression persist beyond active treatment
- →Plan the next course in 3-6 months to reinforce and extend benefits
Month 2-6 (inter-course period)
What you might notice
- •Sustained improvements in respiratory function and pulmonary defense
- •Ongoing geroprotective benefits from persistent bronchial epithelial normalization
- •Reduced frequency and severity of respiratory issues
- •Benefits may gradually diminish over months, indicating readiness for the next course
What's normal
- •Epigenetic modifications to bronchopulmonary genes persist beyond active treatment
- •Khavinson protocols are designed as cyclical treatments with 3-6 month intervals
- •Each subsequent course reinforces and extends benefits from previous treatments
- •Long-term clinical follow-up supports sustained benefits with repeated courses over years
What's next
- →Begin the next Chonluten course after 3-6 months
- →Consider combining with complementary bioregulators (Vladonix, Epithalon) in rotation
- →Comprehensive anti-aging protocols may use Chonluten alongside other organ-specific peptides
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Chonluten over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line"
Avolio F, Martinotti S, Khavinson VK, 2022
Finding: Chonluten peptide and other tissue-specific peptides suppress TNF and inflammatory cytokines in immune cells, acting as natural inducers of inflammation tolerance during infections and tissue damage.
View Study"Short Peptides Stimulate Hepatocyte Migration and Proliferation through the CXCR4 Receptor"
Khavinson VK, Linkova NS, Diatlova A, 2020
Finding: Research (2020) on chonluten contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium"
Khavinson VK, Linkova NS, Kvetnoy IM, 2013
Finding: Research (2013) on chonluten contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Molecular Aspects of Anti-aging Effect of Short Peptides"
Khavinson VK, Linkova NS, Tarnovskaya SI, 2021
Finding: Research (2021) on chonluten contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Geroprotective Effect of Thymalin and Epithalon"
Khavinson VK, Morozov VG, 2003
Finding: Thymic and pineal peptides (Thymalin and Epithalamin) reduced mortality in elderly patients by 2-4 fold over 6-8 years while improving cardiovascular, immune, and metabolic function.
View StudyFrequently Asked Questions